5/28
08:00 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $142.00 price target on the stock, down previously from $157.00.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $142.00 price target on the stock, down previously from $157.00.
5/28
08:00 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $142.00 price target on the stock, down previously from $157.00.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $142.00 price target on the stock, down previously from $157.00.
5/28
06:10 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
5/28
06:10 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
5/20
08:03 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $166.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $166.00 price target on the stock.
5/20
06:29 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
5/20
06:29 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
5/17
07:42 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
5/17
07:42 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
5/14
08:44 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $180.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $180.00 price target on the stock.
5/14
08:23 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
5/14
08:23 am
srpt
Rating for SRPT
Low
Report
Rating for SRPT
5/3
02:51 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
5/2
12:13 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
5/2
12:11 pm
srpt
Rating for SRPT
Low
Report
Rating for SRPT
5/2
08:11 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $166.00 price target on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $166.00 price target on the stock.
5/2
06:50 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
5/2
06:50 am
srpt
Rating for SRPT
Medium
Report
Rating for SRPT
3/5
06:21 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.